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1. Introduction  
Randomized Controlled Trials (RCTs) are the most valuable study which play an important 
role in the field of medicine. Other study types including descriptive studies (e.g. case 
reports, case series, cross-sectional studies) and certain analytical studies (e.g. case control 
studies, cohort studies) are also important pieces of evidence but RCTs which are designed 
for evaluation of the interventions in clinical practice are probably the highest level of 
evidence in the pyramid of Evidence Based Medicine. It is simple, yet the most powerful 
tool in modern clinical research.  
2. RCTs: Top of the evidence-pyramid  
RCTs are considered the most powerful evidence that exists. This is most probably due to 
the fact that ‘randomizing’ people into two different groups probably takes care of all the 
confounding factors and equals out all the causes which may affect the final result of the 
study. 
This is mostly because of their accurate design. This reduces any possibility of bias in the 
result. Every year, the numbers of RCTs that are published in Medical Journals are 
increasing and thus, they have a great effect on changing the way medical science is 
practiced all over the world. Evidence-Based Medicine is highly dependent on the RCTs. 
Therefore designing, conducting and reporting RCTs is an important aspect of medical 
science and all medical professionals should learn these skills. Critical appraisal of RCTs is 
probably as important as conducting them. All medical professionals need to understand 
and evaluate RCTs for the possibility of bias or any shortcomings. RCT results translate 
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directly into changing clinical practice. Hence, it is important that they are free of bias and 
are strong in their design and execution. 
3. RCTs: The other side of the coin 
However, RCTs are not far from their fair share of disadvantages. They may be the most 
powerful tool in the world of research but many ethical and practical concerns limit their 
use.  
3.1. Not all randomized trials are unethical. However, a RCT may be ethical but infeasible. 
This may be due to difficulties in randomization or recruitment. For example, interventions 
like cancer screening at an early age might have an extremely long follow up with not may 
positive outcomes.  
3.2. Once a convention is set in the community or a particular intervention gains popularity, 
it is tough convincing the subjects to “experiment” with their alternative options. A recent 
attempt to conduct a trial of counselling in general practice failed when practitioners 
declined to recruit patients to be allocated at random. 
3.3. Certain populations of people may have certain strong ideologies and preferences. This 
may also limit recruitment and result in bias outcomes if not accounted for and 
accommodated within the study design. 
3.4. Randomised trials are not always practical for evaluation of rare diseases or rare 
outcomes or even outcomes which take a long time to develop.  
3.5. A successful and valid RCT requires a large sample size because the outcomes generally 
have smaller effects and a large measurable difference is required when comparing two 
groups of interventions. So, the larger the sample size, the better the randomized trial but 
the larger the financial constraints as well as the time required for the trial to be completed. 
3.6. They also have a fairly large drop-out rates and a huge population of the sample size is 
often lost to follow up making it even harder to assess the final results.  
3.7. Even with the people who do follow up, not all religiously adhere to the regimen 
prescribed to them and some may even be totally non-compliant.  
3.8. Since they require a lot of time and manpower, they are fairly expensive to conduct. 
Financial constraints are probably the most common reason for a trial to be shelved. 
3.9. Randomized trials have a huge ethical dilemma. If an intervention is considered inferior 
to the current treatment modality, exposing some patients to it and not others (or exposing 
one group to placebo and the other to the treatment) is often thought unethical. For 
example, a non-random study suggested that multivitamin supplementation during 
pregnancy could prevent neural tube defects in children. Even though the study was 
seriously flawed, ethics committees were unwilling to deprive patients of this potentially 
useful treatment, making it difficult to carry out the trial which later showed that folic acid 
was the effective part of the multivitamin cocktail. 
Thus, these randomized trials should only be undertaken if there is an important question 
which needs to be answered by the physician and other small scale observational or 
analytical studies justify its conduction. 
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4. Justification of your trial: Ask two keys questions 
A simple way of knowing if you should go through the trouble of conducting the 
randomized trial is to ask yourself these two simple questions: 
4.1. Is the intervention well enough developed to permit evaluation? 
This can be especially difficult to decide when new interventions are heavily dependent on 
clinicians’ skills (surgical procedures7 or “talk” therapies). 
4.2. Is there preliminary evidence that the intervention is likely to be beneficial (from 
observational studies), including some appreciation of the size of the likely treatment effect?  
Such information is needed to estimate sample sizes and justify the expense of a trial. 
However, there is another side of the story. Failure to perform these important trials which 
should have been conducted may sometimes result in harmful treatments being used 
continuously without validation and evaluation. For example, neonates were widely treated 
with high concentrations of oxygen until randomized trials identified oxygen as a risk factor 
for retinopathy of prematurity. 
Other study designs, including non-randomised controlled trials, can detect associations 
between an intervention and an outcome. But they cannot rule out the possibility that the 
association was caused by a third factor linked to both intervention and outcome. Double 
blinding ensures that the preconceived views of subjects and clinicians cannot 
systematically bias the assessment of outcomes.   
5. History of randomised controlled trials 
Daniel Judah has been thought to have conducted the first and earliest recorded clinical trial 
which dates back to approximately 600 B.C. He compared the health effects of the 
vegetarian diet with those of a royal Babylonian diet over a 10-day period. The trial was 
obviously not even close to the current modern standards set for trials and was majorly 
flawed with allocation bias, ascertainment bias, and confounding by divine intervention, but 
the report has influenced medical decision for now over two millennia. 
The 19th century saw a steep development curve in the history of clinical trials. In 1836, the 
editor of the American Journal of Medical Sciences wrote an introduction to an article that he 
considered “one of the most important medical works of the present century, marking the 
start of a new era of science,” and stated that the article was “the first formal exposition of 
the results of the only true method of investigation in regard to the therapeutic value of 
remedial agents.” This article was the French study on bloodletting in treatment of 
pneumonia by P. C. A. Louis. Sir Austin Bradford Hill takes all the credit for the modern 
concepts of randomization trials. The Medical Research Council trials on streptomycin for 
pulmonary tuberculosis are rightly regarded as a landmark that ushered in a new era of 
medicine. Since Hill’s pioneering achievement, the methodology of the randomized 
controlled trial has been increasingly accepted and the number of randomized controlled 
trials reported has grown exponentially. The Cochrane Library already lists more than 
150,000 such trials, and they have become the underlying basis for what is currently called 
“evidence-based medicine”  
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6. Evidence supporting randomised trials 
Enough evidence exists that a successful RCT is one which is well-designed. These RCTs are 
superior to other study designs in estimating an intervention’s true effect. Meta-analysis of 
controlled trials shows that failure to conceal random allocation and the absence of double 
blinding yield exaggerated estimates of treatment effects. 
It is also well known that well-matched comparison-group designs may be a good 
alternative when an RCT is not feasible.  
7. Issues in designing and conducting RCTs 
As, mentioned before RCTs are conducted to evaluate the importance of an intervention of 
any sorts. They can be used to understand the effectiveness of a screening test or the effect of 
any surgical or medical intervention by comparing the outcomes like mortality or disease 
recurrence. 
Let’s discuss several important issues in designing and conducting of RCTs. 
7.1 Inclusion and exclusion criteria 
In all study types the researchers need to define their target population and the criteria for 
inclusion and exclusion of every individual in the study. This forms an important aspect of 
the trial which needs to be decided before starting the trial. 
Accurate definition of the study population in RCTs is extremely important and some key 
pointers are: 
7.1.1. In RCTs, the researcher needs to make an intervention on the study population and it 
is required that these candidates in the study are eligible for receiving the intervention 
according to the current guidelines.  
7.1.2. If the intervention is contraindicated in a population, then that population meets the 
exclusion criteria of the study target. 
7.1.3. Sometimes it is difficult to assess the effect of an intervention in a large population 
because that needs a large sample size. So the researcher intervenes on a specific portion of 
the population (for example a specific sex or age group). 
7.1.4. Case selection bias is one of the most important bias in RCTs which can be prevented 
by using appropriate inclusion and exclusion criteria.  
Sometimes, the same criteria can be used as either for inclusion or exclusion from the study. 
For example, a specific drug reaction can serve as both depending on what the researcher 
wants to study. It can be an inclusion criterion if the study is about a particular drug and the 
associated adverse reaction. It can also be an exclusion criterion in case the investigator 
wants to analyze the efficacy of the drug. 
The researchers need to report the exact number of the individuals assessed intending to 
meet the inclusion criteria, the exact number of individuals included in the study after 
fulfilling all inclusion and exclusion criteria, the exact number of individuals excluded from 
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the study at the end along with the reasons for the same. It is useful to note that 
unwillingness of an individual to receive the intervention is an exclusion criterion. 
7.2 Study designs  
All randomized trials usually have similar study design. However, still some differences 
exist. If classified according to the patient exposure and the response to the intervention, the 
following styles exist: 
7.2.1 Parallel design 
This is the most popular design and is based on the comparison of the effects of the 
intervention in the case group with the control group or another intervention group. The 
two groups receive a maximum of one intervention. Normally two parallel groups with 
equal sample size will be selected through a randomized selection. However, at times the 
number of the two groups isn’t equal. It is important that the researcher reports this as well 
as the ratio of the individuals in the two groups at the time of reporting the trial.  
Randomized trials can also be done by involving more than two groups. It is then known as 
a multi-arm parallel RCT. 
7.2.2 Cross-over design 
Each participant receives all the interventions involved in the trial. The sequential order in 
which they receive them is decided randomly. This study design however should be limited 
to stable chronic conditions where the disease profile doesn’t fluctuate over time as well as 
short interventions. Also a key concern in these trials is the adequate washout period 
between the two therapies in order to avoid the carry-on effect. 
7.2.3 Factorial design 
This is a complex design where more answers can be found in a single trial. The two or more 
interventions are compared between themselves as well as a control group. Since RCTs are 
expensive to conduct, it’s better that we get more answers in a single trial. 
Due to such differences, it is important that the study design is described in detail at the 
time of reporting the trial. This helps the reader a much better understanding of the research 
conducted. All the study designs must be considered and the best one chosen at the time of 
designing one’s RCT. 
Usually the study design is fixed once the protocol is submitted and the researchers don’t 
change it till end of the study. However, sometimes there is need to modify the study due to 
various reasons. It is important that researchers explain the cause of the same and also the 
outline the changes in the RCT design in detail. 
7.3 Intervention 
One of the most important issues in RCTs is the intervention. Researchers need to answer 
several questions about this aspect before even starting their trial. 
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An intervention can be a drug or device. It can be used for prevention or treatment. For 
drugs it is important to carefully determine the dosage, timing, duration and administration 
route. All information about the drug needs to be provided to the reader at the time of 
reporting. Even the manufacturer of the drug or device can be mentioned for the sake of 
complete reporting and easy reproducibility of the trial if required. 
Even very small differences either in the type, dosage, duration or the route of 
administration may lead to a significant difference in the outcomes. The intervention should 
be obvious in order to give the possibility of comparison to other study to the researchers as 
well as a chance to reproduce the results if required.  
7.4 Outcome/ Results 
Probably the most important think we are looking for in a randomized trial article are the 
outcomes or the results. These can be divided into primary and secondary outcomes. They 
should have been determined before even starting the study.  
Primary outcome is the main intervention outcome. Other study outcomes aer put in the 
category of secondary outcomes. For example the drug side effects are usually put in that 
category.  
Another important issue in the outcomes is the ‘measures’ used to measure these outcomes. 
The outcomes may be laboratory test results. For these outcomes, it is important to list the 
methodology for the measurement, kits used for the same as well as the manufacturer 
where they are produced.  
Other type of outcome is the clinical outcome. For this, it is important to mention the 
guidelines used by the researcher for the determination of the variable as well as the name 
of that person (e.g. General physician, specialists or medical students). 
It is recommended that before selection of the primary and secondary outcomes the 
researchers reviews the literature thoroughly and chooses the similar outcomes in similar 
studies. This is important for comparing the results of the evidence already out there with 
their study. 
An advantage of designing a trial with clearly pre-determined inclusion criteria/exclusion 
criteria, intervention and outcomes which are similar to other studies, is the possibility of 
collecting these data to form a meta-analysis which gives us even more clarity and 
consolidates all the evidence to give a final conclusion. 
7.5 Sample size  
A small sample size is unable to show all differences between case and control group. As 
we mentioned before, the effects are usually small and thus, we need to demonstrate large 
results to show sizable difference and this is why we need a large sample size. However, 
large sample sizes need more time and budget. There are also issues with recruitment and 
reaching out to large populations. Sample size should be determined after a thorough 
literature review and full access to previous studies in populations similar to the current 
study and also after determination of the power of the study. The sample size is the 
answer to the power of the study and simply answers the question: how many 
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participants are needed in order to show the difference in a particular outcome in a 
certain statistical significance? 
Sample size should be determined using sample size calculator software or the standard 
formula. It is recommended to consult a statistician for calculation of the study sample 
size. 
7.6 Randomization 
Randomization is what gives the RCTs its strength. In RCTs patients are randomly assigned 
into the two or more study groups and each individual has an equal chance to be assigned 
to any group. The clinician, the investigators or the patient have no choice in the allocation. 
This prevents the selection bias. Random allocation ensures no systematic differences 
between intervention groups in factors, known and unknown, that may affect outcome. No 
other study design allows this kind of a balance. It is crucial that the investigators pre define 
the allocation guidelines and stick by it till the end of the trial. It is extremely important that 
the guidelines are not modified at any point in the trial. Randomization can be done in 
several different methods. 
The easiest method to do randomization of the sample is ‘simple randomization’. In this 
method, individuals are assigned equally to the groups using a random process, for example, a 
computer generated list of random numbers. Other methods like blocked randomization and 
stratified randomization are more complex, less common and are usually used for very 
specific trials. Blocked randomization aims to numerical balance between groups and stratified 
randomization aims to balance characteristics between the groups. 
7.7 Blinding 
Blinding means that the person is not aware of what group he/she is in and what treatment 
or placebo he/she is receiving. According to the various levels of blinding like blinding the 
participants, researchers, outcome assessors and statisticians, RCTs are divided into four 
types: open label, single blinded, double blinded and triple blinded RCTs. Due to confusions 
and discrepancies about who exactly was blinded in the single and double and triple 
blinded studies, The 2010 CONSORT guidelines specify that authors should not use these 
terms. It is required to report the details of the blinding like "If done, who was blinded after 
assignment to interventions (for example, participants, care providers, those assessing 
outcomes) and how." 
Blinding obviously helps to prevent personal bias in the study which is a huge concern in 
conducting a RCT. Every effort should be made to reduce any bias as much as possible. In 
case the study population is neonates, researchers may decide not to use blinding because of 
the differences in interventions like oral or IV feeds. The most prevalent type of blinding is 
the double blinded design where the investigator and the patient are both unaware of the 
details of who is in which group. 
7.8 Statistical analysis 
The most common statistical tests used for all type of papers are descriptive. These tests 
include mean and standard deviation for quantitative variables and frequency and 
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percentage for qualitative variables. They also use Chi-square test or Exact fisher test for 
comparison and the T tests are also commonly used. Other descriptive statistical tests are 
less commonly used. However, researchers may need other statistical tests for subgroup 
analysis and adjusted analysis. 
Two main ways to analyze RCTs are per protocol analysis and intent to treat analysis. In per 
protocol analysis, analysis will be done based on the groups which the patients are assigned 
into, but in intent to treat analysis the analysis is based on receiving treatment or not. 
Some RCTs need large sample sizes and may continue for a long time. The researchers may 
decide to cease the study if significant difference was observed in important study 
outcomes. For example if a specific drug be associated with significant increase in a side 
effect, then the study should be stopped. Also if a significant improvement be observed 
during the study, the researchers can stop the study. To reach this aim interim analysis can 
be done. But the number of interim analysis, the time, the individuals who will do it and the 
conditions in which the study will stop should be clear. 
8. Clinical trial registry 
All RCTs need to be registered in international clinical trial registry databases before starting 
enrolment of study participants. Once the researchers register their clinical trial in a clinical 
trial registry database they will receive a unique trial registry number. 
Almost all medical journals request their authors mention their trial registry number in the 
abstract of their paper. The editors of these journals avoid publication of RCTs without trial 
registry number even if they have high quality in study design and writing. 
According to the registry database where the researchers register their clinical trial, detailed 
information about the trial is needed by them. 
This information includes: Title, purpose, condition which the study is studying in detail, 
type, name and dosage and all other information about the intervention, study type, 
allocation, endpoints and outcomes, intervention model, masking (Blinding), the number of 
patient enrolled in the study, study start and completion dates, inclusion and exclusion 
criteria etc. 
RCT registration has several benefits. They are a good source of previous trials and it is 
possible to search and reach the content of the registered RCTs easily. 
During the registration the researchers needs to review all important issues in the study 
design and methodology of the research. This helps them to reduce bias in their design and 
consider all aspect of the RCT design. 
All RCTs need to obtain the ethics approval of the committee of the institute or the hospital 
where they want to conduct the trial. This practice will guarantee that all the RCTs 
published in the top-notch high impact medical journals are validated and ethically correct. 
The International Clinical Trial Registry Platform (ICTRP) has introduced ten primary 
registries in its registry network which can register the clinical trial with their profile and the 
link to their website 
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 Australasian New Zealand Clinical Trial Registry 
 Brazilian Clinical Trial Registry 
 Chinese Clinical Trial Registry 
 Clinical Research Information Service (CRIS) , Republic of Korea 
 Clinical Trial Registry – India 
 Cuban Public Registry of Clinical Trials 
 EU Clinical Trial Registry 
 German Clinical Trial Registry 
 Iranian Registry of Clinical Trials 
 Japan Primary Registries Network 
9. Summary 
Randomised controlled trials are the most rigorous way of determining whether a cause-
effect relation exists between treatment and outcome and for assessing the cost effectiveness 
of a treatment. Some key pointers at a glance are: 
9.1. Random allocation to intervention groups 
9.2. Patients and trialists should remain unaware of which treatment was given until the 
study is completed-although such double blind studies are not always feasible or 
appropriate 
9.3. All intervention groups are treated identically except for the experimental treatment 
9.4. Patients are normally analysed within the group to which they were allocated, 
irrespective of whether they experienced the intended intervention (intention to treat 
analysis) 
9.5. The analysis is focused on estimating the size of the difference in predefined outcomes 
between intervention groups. 
Given that poor design may lead to biased outcomes, investigators should strive for 
methodological rigour and report their work in enough detail for others to assess its 
quality. 
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